Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
5
Expiration
Dec 4, 2026
DTE
21d
Moneyness
ITM
Intrinsic
$1.01
IBRX 5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $3.30 | +8.20% | 2 | 305 |
| Nov 20, 2026 | 7d | $4.85 | -6.73% | 4 | 8 |
| Nov 27, 2026 | 14d | $3.35 | +0.00% | 14 | 5 |
| Dec 4, 2026 | 21d | $3.45 | +0.00% | 6 | 3 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | — | — | 0 | 277 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $3.35 | -9.46% | 36 | 26,368 |
| Mar 19, 2027 | 126d | $3.50 | +2.94% | 2 | 369 |
| Apr 16, 2027 | 154d | $5.70 | +9.62% | 2 | 25 |
| May 21, 2027 | 189d | $4.00 | +4.17% | 10 | 85 |
| Aug 20, 2027 | 280d | $4.50 | -15.09% | 1 | 232 |
| Nov 19, 2027 | 371d | $4.70 | +17.79% | 5 | 109 |
| Jan 21, 2028 | 434d | $4.29 | -5.09% | 46 | 10,993 |
| Mar 17, 2028 | 490d | $5.90 | -3.28% | 5 | 385 |
| Jan 19, 2029 | 798d | $5.20 | +4.00% | 3 | 323 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.